Skip to content
X-twitter
Linkedin
Youtube
FR
EN
FR
EN
HERV Approach
A novel approach
HERV in MS
HERV in Post-COVID
HERV in ALS
Other HERV-mediated diseases
Pipeline Overview
Intellectual Property
Post-COVID
HERV in Post-COVID
Clinical trial
Publications
Clinical Trials
News & Media
News & Press
Scientific publications
Investors
GNRO Shares
GeNeuro’s main shareholders
Analyst coverage
Stock price
Press releases
Annual reports / Registration documents
AMF Regulated information
Company governance
Financial events
Investor relations
About GeNeuro
Company Overview
Company History
The Board of GeNeuro
Management
General meetings
Contact
Menu
HERV Approach
A novel approach
HERV in MS
HERV in Post-COVID
HERV in ALS
Other HERV-mediated diseases
Pipeline Overview
Intellectual Property
Post-COVID
HERV in Post-COVID
Clinical trial
Publications
Clinical Trials
News & Media
News & Press
Scientific publications
Investors
GNRO Shares
GeNeuro’s main shareholders
Analyst coverage
Stock price
Press releases
Annual reports / Registration documents
AMF Regulated information
Company governance
Financial events
Investor relations
About GeNeuro
Company Overview
Company History
The Board of GeNeuro
Management
General meetings
Contact
GNRO Shares
GeNeuro’s main shareholders
Analyst coverage
Stock price
Press releases
Presentations
Annual reports / Registration documents
AMF Regulated information
Company governance
General meetings
Financial events
Investor relations
GNRO Shares
GeNeuro’s main shareholders
Analyst coverage
Stock price
Press releases
Presentations
Annual reports / Registration documents
AMF Regulated information
Company governance
General meetings
Financial events
Investor relations
Company governance
Articles of Association (in French) - status as of June 14, 2023
Organization rules (in French)
